What is OSA?
OSA occurs when the muscles in the throat relax excessively during sleep, causing the soft tissues to collapse and block the upper airway. This stops breathing for periods ranging from 10 seconds to over a minute.
Where We Are Now
The Asset
Sleepiz One+ rewrites the user experience by making monitoring invisible. It is a radar-based device that sits on the bedside table - completely contactless, no wearables, no wires. It offers a 'set it and forget it' experience while delivering medical-grade data. It is already CE-marked, FDA-cleared as a vital signs monitor and boasts a powerful 0.94 correlation with the burdensome PSG gold standard.
The Proposal
We are looking to bridge the gap between 'vital sign monitor' and 'regulatory endpoint'. Our goal is to deploy Sleepiz One+ specifically within metabolic clinical trials to collect primary, secondary, and exploratory OSA endpoints. We aim to prove that this low-burden technology can generate the robust evidence required to support regulatory filings and label claims.
The Opportunity
We are calling on pharmaceutical innovators developing novel weight-loss therapies to join this program. If you are ready to look beyond the scale and capture the full therapeutic value of your asset without burdening your patients, we want to work with you.
Join us to co-create the evidence package that establishes contactless monitoring as the new standard for metabolic trials. Click here for more information.
Let's validate the future of sleep measurement together.
Key Details
Regulatory Status: CE-Marked (EU), FDA 510(k) Cleared (Vital Signs)
Validated Accuracy: Correlation of rₚ = 0.94 with PSG-derived AHI; sensitivity 88%, specificity 98%.
Timeline: Open for immediate collaboration
Interested in learning more about this initiative? Read more here.
Sign up for our newsletter to receive the latest solutions, new opportunities and expert insights on digital health measures delivered to your inbox.